Cancer patients are at an increased risk of developing venous thromboembolism (VTE), which includes both deep vein thrombosis (DVT) and pulmonary embolism (PE). Thrombosis is a common complication in cancer patients due to the hypercoagulable state induced by malignancy and its treatments. DOACs offer an effective and convenient option for managing this risk.
